ライフサイエンスコーパス: multivessel disease

1 ne vessel (13 with single-vessel and 17 with multivessel disease).

2 onary atherosclerosis and more than half had multivessel disease.

3 DASE was greater specificity, especially for multivessel disease.

4 coronary artery bypass surgery, and 65% had multivessel disease.

5 n data has shown to improve the detection of multivessel disease.

6 is now commonly used to treat patients with multivessel disease.

7 in insulin-requiring diabetic patients with multivessel disease.

8 n of left ventricular function and extent of multivessel disease.

9 the other diseased vessels in patients with multivessel disease.

10 patterns for patients with single-vessel and multivessel disease.

11 is of > or = 50% and 114 patients (55%) with multivessel disease.

12 nd moderately sensitive (68%, 77 of 114) for multivessel disease.

13 outcome than was angiographically determined multivessel disease.

14 nosis in patients with cardiogenic shock and multivessel disease.

15 perfusion capacity in eligible patients with multivessel disease.

16 -segment-elevation myocardial infarction and multivessel disease.

17 mic left ventricular dysfunction (iLVSD) and multivessel disease.

18 ion, silent ischemia, history of stroke, and multivessel disease.

19 ascular events in patients with acute MI and multivessel disease.

20 patients with myocardial infarction (MI) and multivessel disease.

21 ascularization in patients with acute MI and multivessel disease.

22 I versus CABG for the treatment of iLVSD and multivessel disease.

23 s had left main (LM) disease with or without multivessel disease.

24 elevation myocardial infarction (STEMI) have multivessel disease.

25 h single-vessel disease, and 22 (25.3%) with multivessel disease.

26 ete revascularization (ICR) in patients with multivessel disease.

27 -segment-elevation myocardial infarction and multivessel disease.

28 morbidities, including cardiogenic shock and multivessel disease.

29 rm safety of FFR-guided PCI in patients with multivessel disease.

30 onary intervention (PCI) among patients with multivessel disease.

31 segment-elevation myocardial infarction have multivessel disease.

32 e analysis was restricted to only those with multivessel disease.

33 was cost-effective as compared with PTCA for multivessel disease.

34 ts, aged patients had a higher prevalence of multivessel disease (16.5% vs. 9.6%, p = 0.001), unstabl

35 d no significant change in the prevalence of multivessel disease (24 percent in 1980-1981 and 23 perc

36 25.5 vs. 40.1%, p = 0.047), anterior MI, and multivessel disease (34.8 vs. 77.8%, p < 0.001) and a sh

37 IQR: 64-80 years], P = 0.007), less frequent multivessel disease (39% vs. 51%, P = 0.029), less frequ

38 ction <14 days = 7; elevated creatinine = 4; multivessel disease = 4; and age >65 years = 3.

39 rfusion defects were similarly sensitive for multivessel disease (72%, 42/58 vs. 66%, 38/53, respecti

40 g 16,089 patients with diabetes mellitus and multivessel disease, 8096 patients with similar propensi

41 Multivessel disease (87% versus 74%, P = .01) was more f

42 84%, 51/61 vs. 74%, 45/61, respectively) and multivessel disease (91%, 53/58 vs. 86%, 50/58, respecti

43 luding older age, extreme body mass indexes, multivessel disease, a lower ejection fraction, unstable

44 ts isolated and is often in combination with multivessel disease, a treatment algorithm with medical

45 l, we randomly assigned 706 patients who had multivessel disease, acute myocardial infarction, and ca

46 t-Only Revascularization Strategies to Treat Multivessel Disease after Early PCI for STEMI (COMPLETE)

47 rsus Culprit-Only Revascularization to Treat Multivessel Disease After Early PCI for STEMI), a strate

48 coronary artery disease in both single- and multivessel disease and detects more subendocardial isch

49 The accuracy was high in single-vessel and multivessel disease and independent of CAD location.

50 Bypass surgery for patients with multivessel disease and ISR provided the best outcomes.

51 Among patients with multivessel disease and MI-related CS, CR is achieved on

52 heart failure class III or higher, thrombus, multivessel disease and older age.

53 e the elevated risk of CABG in patients with multivessel disease and planned IR remains to be determi

54 Patients with multivessel disease and severe left ventricular systolic

55 Among patients with multivessel disease and severe left ventricular systolic

56 percutaneous coronary intervention (PCI) for multivessel disease and severe left ventricular systolic

57 of ICR to adverse outcomes in patients with multivessel disease and stable ischaemic heart disease,

58 particularly in patients with more extensive multivessel disease and the greatest degree of left vent

59 eous coronary interventions in patients with multivessel disease and the recent introduction of drug-

60 occurred within the context of a decline in multivessel disease and thus likely reflect the natural

61 s graft surgery, especially in patients with multivessel disease and unprotected left-main stem coron

62 ity (p = 0.036) were higher in patients with multivessel disease and were similar for both treatment

63 lder, women, hypertensive and diabetic, with multivessel disease and with reduced left ventricular fu

64 (131 had single-vessel disease [SVD]; 30 had multivessel disease), and 310 (60.1%) had >/=50% stenosi

65 presenting with acute myocardial infarction, multivessel disease, and cardiogenic shock.

66 oronary artery disease, P = 0.81 for that of multivessel disease, and P = 0.57 for the mean degree of

67 , previous angioplasty or bypass surgery and multivessel disease, and we sequentially compared Braunw

68 yocardial infarction, cardiogenic shock, and multivessel disease, and were associated with higher mor

69 rity of patients with cardiogenic shock have multivessel disease, and whether PCI should be performed

70 -segment-elevation myocardial infarction and multivessel disease; and the ST-segment-elevation myocar

71 der the curve, 0.88 versus 0.73; P<0.001) or multivessel disease (area under the curve, 0.98 versus 0

72 y significant coronary artery disease and of multivessel disease, assessed the mean degree of stenosi

73 rdiac-related health status in patients with multivessel disease at 6- and 12-month follow-up.

74 lute difference (P = 0.01) and percentage of multivessel disease at baseline (P = 0.004).

75 t of 2013) of those patients identified with multivessel disease at NCDR sites had had 0- or 1-vessel

76 onths were female sex (beta 0.123; P=0.002), multivessel disease (beta 0.121; P=0.002), N-terminal pr

77 randomized 11 876 patients with acute MI and multivessel disease, both single-setting complete and st

78 PCI are performed in older patients to treat multivessel disease, but their comparative effectiveness

79 ascularisation of patients with diabetes and multivessel disease by CABG decreases long-term mortalit

80 For patients with multivessel disease, CABG continues to be associated wit

81 For patients with multivessel disease, CABG provided a survival advantage

82 In subgroup analysis of multivessel disease, CABG provided significant survival

83 ment-elevation acute coronary syndromes with multivessel disease, choice of revascularization modalit

84 senting with acute myocardial infarction and multivessel disease, complete revascularisation reduced

85 -segment-elevation myocardial infarction and multivessel disease, complete revascularization reduced

86 isk of adverse events, a higher incidence of multivessel disease, complex lesions, and visible thromb

87 Elderly Myocardial Infarction Patients With Multivessel Disease) confirmed the benefit of complete r

88 Among patients with multivessel disease, contemporary PCI resulted in safer

89 In patients with diabetes mellitus and multivessel disease, coronary artery bypass graft surger

90 ICERs, including patients with >1 prior MI, multivessel disease, diabetes, renal dysfunction (all wi

91 detect residual infarct artery stenosis and multivessel disease during the first week after acute my

92 In patients with diabetes mellitus and multivessel disease, EES was associated with lower upfro

93 Elderly Myocardial Infarction Patients With Multivessel Disease) enrolled 1445 older (aged >=75 year

94 ional Assessment in Elderly MI Patients With Multivessel Disease (FIRE) randomized clinical trial dat

95 ional Assessment in Elderly MI Patients With Multivessel Disease (FIRE), was an investigator-initiate

96 risk (RR) 0.68 (95% CI, 0.45-1.03); P=0.07; multivessel disease following ST-segment-elevation myoca

97 ith Diabetes mellitus: Optimal management of Multivessel disease [FREEDOM]; NCT00086450).

98 arction, inoperable or high surgical risk or multivessel disease had significantly higher 5-year card

99 G for ISR, mainly because of the presence of multivessel disease, had significantly better outcomes t

100 patients with myocardial infarction (MI) and multivessel disease has been shown to reduce cardiovascu

101 Complete revascularization in patients with multivessel disease has been shown to reduce mortality c

102 clinical trial evaluated STEMI patients with multivessel disease having PPCI within 12 h of symptom o

103 Multivessel disease identified through DSE was more pred

104 Diabetes was present in 28% and multivessel disease in 51%.

105 who underwent angiography (p < 0.001), with multivessel disease in 63% versus 13% (p < 0.001).

106 ars) patients with myocardial infarction and multivessel disease in Italy, Spain, and Poland.

107 In patients presenting for P-PCI with multivessel disease, index admission complete revascular

108 In patients with multivessel disease, index segment revascularization was

109 vascularization of symptomatic patients with multivessel disease involving the LAD is warranted.

110 -segment-elevation myocardial infarction and multivessel disease is associated with better outcomes t

111 the early phase post-STEMI in patients with multivessel disease is safe.

112 -segment-elevation myocardial infarction and multivessel disease is uncertain.

113 neous coronary intervention in patients with multivessel disease is unclear in that there is little i

114 elevation myocardial infarction (STEMI) and multivessel disease is unknown.

115 nce imaging (MRI) in patients with STEMI and multivessel disease is warranted.

116 te and high-risk acute coronary syndrome and multivessel disease managed with percutaneous coronary i

117 rvention (PCI) in patients with diabetes and multivessel disease, managed with or without insulin.

118 sought to determine if patients with T1D and multivessel disease may benefit from CABG compared with

119 risk from combined procedures: patients with multivessel disease (multivariable OR 1.64, 95% CI 1.13

120 atients with acute myocardial infarction and multivessel disease, multivessel percutaneous coronary i

121 association between functional significant, multivessel disease (MVD) and reduced culprit final infa

122 with evolocumab was greater in patients with multivessel disease (MVD).

123 Symptomatic patients with multivessel disease (n = 1,829) were randomly assigned t

124 associated with female sex, hyperlipidemia, multivessel disease, N-terminal pro-B-type natriuretic p

125 ional Assessment in Elderly MI Patients With Multivessel Disease]; NCT03772743).

126 were age, anemia, congestive heart failure, multivessel disease, number of stents implanted, and use

127 he predictors of 30-day readmission included multivessel disease (odds ratio [OR], 1.97; 95% CI, 1.65

128 The effect of multivessel disease on inducibility of these perfusion a

129 t anterior descending artery stenosis and/or multivessel disease) or non-high risk.

130 In patients with multivessel disease, overall mortality and freedom from

131 p = 0.001), history of prior MI (p = 0.003), multivessel disease (p = 0.006), and advancing age (p <

132 the following contentions: For patients with multivessel disease, particularly involving the proximal

133 Data from multivessel disease patients in New York's cardiac surge

134 ew York's cardiac registry identified 63,402 multivessel disease patients undergoing coronary artery

135 ation myocardial infarction (STEMI) who have multivessel disease, percutaneous coronary intervention

136 -segment-elevation myocardial infarction and multivessel disease, percutaneous coronary intervention

137 In older patients with MI and multivessel disease, physiology-guided complete revascul

138 revascularization strategy in patients with multivessel disease presenting with cardiogenic shock co

139 aneous coronary intervention (PPCI) who have multivessel disease presenting with ST-segment elevation

140 with culprit-only stenting in patients with multivessel disease presenting with unstable angina or n

141 rt failure than white men but lower rates of multivessel disease, prior coronary artery bypass graft

142 ry endpoints included frequency of detecting multivessel disease, proximal left anterior descending a

143 mortality and MI rates in 1829 patients with multivessel disease randomized to CABG or PTCA.

144 elevation myocardial infarction (NSTEMI) and multivessel disease remain unclear.

145 n strategy in diabetic patients with complex multivessel disease remains controversial.

146 years of age) with myocardial infarction and multivessel disease remains unclear.

147 A total of 60 patients with multivessel disease requiring staged procedure at 1 mont

148 neous intervention in diabetic patients with multivessel disease results in higher mortality than cor

149 nt elevation myocardial infarction (MI) with multivessel disease results in lower major adverse cardi

150 Elderly Myocardial Infarction Patients With Multivessel Disease) showed the superiority of complete

151 it vessel-only PCI (CO-PCI) in patients with multivessel disease, ST-segment-elevation myocardial inf

152 -segment-elevation myocardial infarction and multivessel disease, stress echocardiography-guided reva

153 Killip class >/=2, baseline thrombocytosis, multivessel disease, symptom onset-to-balloon time, and

154 Among STEMI patients with multivessel disease, the benefit of complete revasculari

155 Among patients presenting with STEMI and multivessel disease, the benefit of complete revasculari

156 In patients 75 years or older with MI and multivessel disease, the benefit of physiology-guided co

157 age or older with myocardial infarction and multivessel disease, those who underwent physiology-guid

158 In subgroup analysis of patients with multivessel disease, those with a stent-like result had

159 PET is well suited to patients with multivessel disease to confirm or exclude balanced ischa

160 revascularization in patients with high-risk multivessel disease to optimize their long-term clinical

161 rtery has been investigated in patients with multivessel disease to provide a minimally invasive ther

162 ic patients with acute coronary syndrome and multivessel disease treated with PCI rather than CABG ha

163 entation, diabetes mellitus, current smoker, multivessel disease, treatment of an in-stent restenotic

164 With ST-Elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or

165 ith Diabetes Mellitus: Optimal Management of Multivessel Disease) trial demonstrated that for patient

166 ith Diabetes Mellitus: Optimal Management of Multivessel Disease) trial demonstrated that, on average

167 ional Assessment in Elderly MI Patients with Multivessel Disease) trial, 1,445 older patients with my

168 ith Diabetes mellitus: Optimal management of Multivessel disease) trial, we compared patients receivi

169 gle arterial grafts (SAGs) for patients with multivessel disease undergoing coronary artery bypass gr

170 ltivessel intervention in 3984 patients with multivessel disease undergoing primary percutaneous coro

171 levation myocardial infarction patients with multivessel disease was dependent on the presence of 3-v

172 ecause sensitivity for residual stenosis and multivessel disease was maximal in the high-risk subsets

173 Nonobstructive, single, and multivessel disease was present in 256 (14.5%), 772 (43.

174 However, the ability to detect multivessel disease was reduced with attenuation/scatter

175 es 5-year cardiac mortality in patients with multivessel disease was significantly greater after init

176 The degree of multivessel disease was similar between the two groups.

177 The rate of angiographic multivessel disease was similar in the angiography-guide

178 The extent of significant CAD (single- or multivessel disease) was highly concordant with coronary

179 Patients 75 years or older with MI and multivessel disease were enrolled at 34 European centers

180 tion with everolimus eluting stent (EES) for multivessel disease were included.

181 Diabetes mellitus and multivessel disease were independently associated with i

182 Diabetes mellitus and multivessel disease were more often present in the later

183 The determinants of sensitivity for multivessel disease were peak heart rate and infarct siz

184 on Investigation (BARI), 1,829 patients with multivessel disease were randomized to an initial strate

185 optimal management of patients found to have multivessel disease while undergoing primary percutaneou

186 ction, and heart failure among patients with multivessel disease who are undergoing coronary artery b

187 Patients with NSTEMI and multivessel disease who had successful revascularization

188 andomly assigned 885 patients with STEMI and multivessel disease who had undergone primary PCI of an

189 we randomly assigned patients with STEMI and multivessel disease who had undergone successful PCI of

190 We identified patients with multivessel disease who received drug-eluting stents or

191 a randomized clinical trial in patients with multivessel disease who underwent a successful percutane

192 registries to identify 37,212 patients with multivessel disease who underwent CABG and 22,102 patien

193 y, we compared the outcomes in patients with multivessel disease who underwent CABG with the outcomes

194 who underwent CABG and 22,102 patients with multivessel disease who underwent PCI from January 1, 19

195 In patients with STEMI and multivessel disease who underwent primary PCI of an infa

196 r ST segment or non-ST segment elevated) and multivessel disease who were hospitalized after successf

197 A total of 68.9% of all stent patients with multivessel disease who were studied were IR, and 30.1%

198 lder patients with myocardial infarction and multivessel disease who were undergoing percutaneous cor

199 EMI or very-high-risk non-STEMI (NSTEMI) and multivessel disease who were undergoing primary percutan

200 ase, history of peripheral vascular disease, multivessel disease, widowhood, and lack of private insu

201 ional databases show a survival advantage in multivessel disease with coronary artery bypass grafting

202 sease undergoing index revascularization for multivessel disease with either DES or isolated CABG (n=

203 or high risk for continued medical therapy (multivessel disease with ischemia and/or left ventricula

204 y (ACUITY) trial, 1772 diabetic patients had multivessel disease with left anterior descending artery

205 -segment-elevation myocardial infarction and multivessel disease with successful percutaneous coronar

206 In patients with multivessel disease with successful primary percutaneous

207 ith Diabetes Mellitus: Optimal Management of Multivessel Disease) with prior probability distribution